Anti-DXd/Exatecan monoclonal antibody (mAb)
Utilizing our specific Anti-DXd/Exatecan Monoclonal Antibody can target and quantify, accurately, DXd/Exatecan related ADCs effectively as our product facilitates large-scale pharmacokinetic evaluations. Essential to the understanding of ADCs’ life cycle, such assessment offers a valuable insight of their absorption, distribution, and elimination phases to help optimize use of ADC-based therapies.
Check the Technical
Information
Order information
Catalog No. | Product Name | Size | Price(In USD) |
---|---|---|---|
GTU-Bios-DXd-Ab-1 | Anti-DXd/Exatecan human monoclonal antibody (mAb) | 1mg | 1690 |
GTU-Bios-DXd-Ab-2 | Anti-DXd/Exatecan mouse monoclonal antibody (mAb) | 1mg | 1690 |
GTU-Bios-DXd-Ab-3 | Anti-DXd/Exatecan mouse monoclonal antibody (mAb) | 1mg | 1690 |
Size: 1mg | 10mg | 100mg
Описание
Anti-DXd/Exatecan human monoclonal antibody (mAb)
Cat No. | GTU-Bios-DXd-Ab-1 |
Product Name | Anti-DXd/Exatecan human monoclonal antibody (mAb) |
Target | Deruxtecan (DXd) / Exatecan |
Expression platform | mammalian cell |
Isotypes | Human IgG1 |
Bioactivity validation | Deruxtecan (DXd) / Exatecan binding, Competitive immunoassay validation (Competitive ELISA) in Deruxtecan (DXd) / Exatecan level test. |
Tag | hFc |
Products description | Anti-Deruxtecan (DXd) / Exatecan monoclonal antibody is expressed from mammalian cell. |
Species | Human |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA) and other Immunoassay, PK & PD assay for DXd & Exatecan payload of Antibody-drug Conjugate (ADC). |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-DXd/Exatecan mouse monoclonal antibody (mAb)
Cat No. | GTU-Bios-DXd-Ab-2, GTU-Bios-DXd-Ab-3 |
Product Name | Anti-DXd/Exatecan mouse monoclonal antibody (mAb) |
Target | Deruxtecan (DXd) / Exatecan |
Expression platform | mammalian cell |
Isotypes | Mouse IgG |
Bioactivity validation | Deruxtecan (DXd) / Exatecan binding, Competitive immunoassay validation (Competitive ELISA) in Deruxtecan (DXd) / Exatecan level test. |
Tag | mFc |
Products description | Anti-Deruxtecan (DXd) / Exatecan) mouse monoclonal antibody (mAb) is expressed from mammalian cell. |
Species | Mouse |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Competitive immunoassay validation (Competitive ELISA) and other Immunoassay, PK & PD assay for DXd & Exatecan payload of Antibody-drug Conjugate (ADC). |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Ссылки
Validation Data
- Figure 1: Specific Binding with DXd
- Figure 2: minimal impact on pharmacokinetic (PK) studies
Figure 1. GeneMedi's GTU-Bios-DXd-Ab: Specific Binding with DXd, Not Binding with SN38.
GeneMedi's GTU-Bios-DXd-Ab exhibits specific binding to DXd-based ADCs, demonstrating its effectiveness. Moreover, it does not bind to ADCs conjugated with SN38, underscoring GeneMedi's commitment to producing highly selective antibodies.
Figure 2. GTU-Bios-DXd-Ab has minimal impact on pharmacokinetic (PK) studies involving humans and monkeys.
GTU-Bios-DXd-Ab demonstrates minimal influence in PK studies with humans and monkeys, rendering it appropriate for application in these experiments.
Click to get more Data / Case study about the product.
Связанные продукты
Cat No. | Product Name | Technical Information | Products Information |
---|---|---|---|
GTU-Bios-Maytansinoids-Ab | Anti-DM1/DM4 monoclonal antibody(mAb) | More | Details |
GTU-Bios-Auristatin-Ab-01 | Anti-MMAE/MMAF monoclonal antibody(mAb) | More | Details |
GTU-Bios-Auristatin-Ab-02 | Anti-MMAE (Specific) monoclonal antibody(mAb) | More | Details |
GTU-Bios-DXd-Ab | Anti-DXd&Exatecan monoclonal antibody(mAb) | More | Details |
Leave a comment
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
Comments
No comments yet.